Cardiology Research and Practice [92] L. R. Gao, R. Y. Xu, N. K. Zhang et al., “Increased apelin following bone marrow mononuclear cell transplantation contributes to the improvement of cardiac function in patients with severe heart failure,” Cell Transplantation, vol. 18, no. 12, pp. 1311–1318, 2009. [93] L. R. Gao, N. K. Zhang, J. Bai et al., “The apelin-APJ pathway exists in cardiomyogenic cells derived from mesenchymal stem cells in vitro and in vivo,” Cell Transplantation, vol. 19, no. 8, pp. 949–958, 2010. [94] I. Szokodi, P. Tavi, G. Fo¨ldes et al., “Apelin, the novel endoge- nous ligand of the orphan receptor APJ, regulates cardiac contractility,” Circulation Research, vol. 91, no. 5, pp. 434– 440, 2002. [95] E. A. Ashley, J. Powers, M. Chen et al., “The endogenous peptide apelin potently improves cardiac contractility and re- duces cardiac loading in vivo,” Cardiovascular Research, vol. 65, no. 1, pp. 73–82, 2005. [96] M. F. Berry, T. J. Pirolli, V. Jayasankar et al., “Apelin has in vivo inotropic eﬀects on normal and failing hearts,” Circula- tion, vol. 110, no. 11, pp. II187–II193, 2004. [97] K. Kuba, L. Zhang, Y. Imai et al., “Impaired heart contractility in apelin gene-deﬁcient mice associated with aging and pressure overload,” Circulation Research, vol. 101, no. 4, pp. e32–e42, 2007. [98] P. Atluri, K. J. Morine, G. P. Liao et al., “Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression,” Cellular and Molecular Biology Letters, vol. 12, no. 1, pp. 127–138, 2007. [99] T. Dai, G. Ramirez-Correa, and W. D. Gao, “Apelin increases contractility in failing cardiac muscle,” European Journal of Pharmacology, vol. 553, no. 1–3, pp. 222–228, 2006. [100] M. Hosoya, Y. Kawamata, S. Fukusumi et al., “Molecular and functional characteristics of APJ: tissue distribution of mrna and interaction with the endogenous ligand apelin,” Journal of Biological Chemistry, vol. 275, no. 28, pp. 21061–21067, 2000. [101] C. Wang, J. F. Du, F. Wu, and H. C. Wang, “Apelin decreases the sr Ca2+ content but enhances the amplitude of [Ca2+]i transient and contractions during twitches in isolated rat cardiac myocytes,” American Journal of Physiology, vol. 294, no. 6, pp. H2540–H2546, 2008. [102] A. G. Japp, N. L. Cruden, G. Barnes et al., “Acute cardiovas- cular eﬀects of apelin in humans: potential role in patients with chronic heart failure,” Circulation, vol. 121, no. 16, pp. 1818–1827, 2010. [103] R. Sarzani, C. Forleo, F. Pietrucci et al., “The 212A variant of the APJ receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardiomyopathy,” Journal of Cardiac Failure, vol. 13, no. 7, pp. 521–529, 2007. [104] H. J. Chun, Z. A. Ali, Y. Kojima et al., “Apelin signaling antag- onizes Ang II eﬀects in mouse models of atherosclerosis,” Journal of Clinical Investigation, vol. 118, no. 10, pp. 3343– 3354, 2008. [105] K. Siddiquee, J. Hampton, S. Khan et al., “Apelin protects against angiotensin II-induced cardiovascular ﬁbrosis and decreases plasminogen activator inhibitor type-1 produc- tion,” Journal of Hypertension, vol. 29, no. 4, pp. 724–731, 2011. [106] B. Gurzu, B. C. Petrescu, M. Costuleanu, and G. Petrescu, “Interactions between apelin and angiotensin II on rat portal vein,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 7, no. 4, pp. 212–216, 2006. 11 [107] W. W. Hung, T. J. Hsieh, T. Lin et al., “Blockade of the renin- angiotensin system ameliorates apelin production in 3T3-L1 adipocytes. Cardiovascular drugs and therapy,” Cardiovascu- lar Drugs and Therapy, vol. 25, no. 1, pp. 3–12, 2011. [108] X. Sun, S. Iida, A. Yoshikawa et al., “Non-activated APJ sup- presses the angiotensin II type 1 receptor, whereas apelin- activated APJ acts conversely,” Hypertension Research, vol. 34, no. 6, pp. 701–706, 2011.